AEON Biopharma, Inc.

AEON Biopharma, Inc., identified by SEC CIK 0001837607, is a clinical-stage biopharmaceutical company operating in the therapeutic drug development sector. The company, which entered public markets via the SPAC vehicle structure in 2021, filed a Form 10-Q with the SEC on August 12, 2022, covering its quarterly financial results under accession number 0001104659-22-090142. AEON focuses on botulinum toxin complex therapeutics, positioning itself within the specialty pharma and neurology space. As of the filing date, the company was active as a reporting issuer with ongoing development-stage operations. For complete filing history, sponsor details, deal terms, and screening data on AEON Biopharma and hundreds of other SPAC transactions, sign up for full access at SpacDesk.